Competition critic
Executive Summary
From the Republican side, Oklahoma Rep. Coburn continued his recent attacks on drug pricing and competition. Restricted to one minute by the majority, Coburn charged that the debate was on the wrong subject. "What we are doing is the wrong thing," Coburn said. "The politics of Washington is claiming to fix a problem that is very real, but it is fixing the wrong problem. The problem is there is no competition within the pharmaceutical industry"
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth